Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more
Market Cap & Net Worth: Paradigm Biopharmaceuticals Limited (PBIGF)
Paradigm Biopharmaceuticals Limited (PINK:PBIGF) has a market capitalization of $165.10 Million ($165.10 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #18366 globally and #6851 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Paradigm Biopharmaceuticals Limited's stock price $0.38 by its total outstanding shares 433682549 (433.68 Million).
Paradigm Biopharmaceuticals Limited Market Cap History: 2019 to 2025
Paradigm Biopharmaceuticals Limited's market capitalization history from 2019 to 2025. Data shows change from $863.03 Million to $165.10 Million (-15.78% CAGR).
Paradigm Biopharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Paradigm Biopharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3167.75x
Paradigm Biopharmaceuticals Limited's market cap is 3167.75 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $863.03 Million | $2.98 Million | -$15.63 Million | 289.22x | N/A |
| 2021 | $624.50 Million | $20.55K | -$34.30 Million | 30389.43x | N/A |
| 2022 | $419.11 Million | $79.22K | -$39.25 Million | 5290.20x | N/A |
| 2023 | $118.74 Million | $46.76K | -$51.91 Million | 2539.40x | N/A |
| 2024 | $60.93 Million | $65.80K | -$58.65 Million | 926.02x | N/A |
| 2025 | $165.10 Million | $52.12K | -$18.77 Million | 3167.75x | N/A |
Competitor Companies of PBIGF by Market Capitalization
Companies near Paradigm Biopharmaceuticals Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Paradigm Biopharmaceuticals Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Paradigm Biopharmaceuticals Limited Historical Marketcap From 2019 to 2025
Between 2019 and today, Paradigm Biopharmaceuticals Limited's market cap moved from $863.03 Million to $ 165.10 Million, with a yearly change of -15.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $165.10 Million | +170.96% |
| 2024 | $60.93 Million | -48.69% |
| 2023 | $118.74 Million | -71.67% |
| 2022 | $419.11 Million | -32.89% |
| 2021 | $624.50 Million | -20.00% |
| 2020 | $780.63 Million | -9.55% |
| 2019 | $863.03 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Paradigm Biopharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $165.10 Million USD |
| MoneyControl | $165.10 Million USD |
| MarketWatch | $165.10 Million USD |
| marketcap.company | $165.10 Million USD |
| Reuters | $165.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.